Viatris Inc. VTRS
17.83
0.41
2.35%
as of 25 Sep
- Market cap
- $20.0B
- P/E
- 0.0×
Follow VTRS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Viatris Inc. (VTRS) Net income
Viatris Inc.'s net income for fiscal 2025 was −$3.5B, compared with −$634.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$410.7M. Over the past ten years it has ranged from −$3.5B (fiscal 2025) to $2.1B (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Viatris Inc. ranks 85th of 86 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Annual
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$3.5B | — |
| FY2024 | −$634.2M | — |
| FY2023 | $54.7M | (97.37%) |
| FY2022 | $2.1B | — |
| FY2021 | −$1.3B | — |
| FY2020 | −$669.9M | — |
| FY2019 | $16.8M | (95.23%) |
| FY2018 | $352.5M | (49.35%) |
| FY2017 | $696.0M | 45.00% |
| FY2016 | $480.0M | (43.38%) |
Quarterly
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$118.8M | — |
| Mar 2026 | $176.4M | — |
| Dec 2025 | −$340.1M | — |
| Sep 2025 | −$128.2M | — |
| 42 more quarters | Free account |
Against its own ten years
Low −$3.5B
High $2.1B
Ten-year median
$54.7M
Current reading's percentile
9
Net income against peers
| Company | Net income |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $3.1B |
| ZTS Zoetis Inc. compare | $2.6B |
| UTHR United Therapeutics Corporation compare | $1.3B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $709.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $705.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $334.0M |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
| VTRS Viatris Inc. | −$410.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on VTRS
- Revenue
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement